NCT05687253View on ClinicalTrials.gov

Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 25, 2022

Primary Completion Date

April 10, 2023

Study Completion Date

May 8, 2023

Conditions
Neuromuscular BlockadeAnesthesiaSurgery
Interventions
DRUG

BX1000

IV BX1000

DRUG

Rocuronium Bromide

IV Rocuronium

Trial Locations (2)

78240

Research Center, San Antonio

84107

Research Center, Salt Lake City

Sponsors

Lead Sponsor

Baudax Bio
All Listed Sponsors
lead

Baudax Bio

INDUSTRY

NCT05687253 - Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery | Biotech Hunter | Biotech Hunter